Clinical Trials Logo

Filter by:
NCT ID: NCT02145741 Completed - Neoplasms Clinical Trials

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Start date: June 11, 2014
Phase: Phase 1
Study type: Interventional

This open-label dose escalation phase I trial, 1280.15, is with the first administration of BI 836845 in Japanese patients with various types of advanced solid tumours. The rationale behind this study is to identify the maximum tolerated dose (MTD) of BI 836845 in Japanese patients with advanced solid tumours as weekly intravenous administration.

NCT ID: NCT02143635 Completed - Clinical trials for Advanced Solid and Hematological TP53wt Tumors

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Start date: July 7, 2014
Phase: Phase 1
Study type: Interventional

To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.

NCT ID: NCT02143466 Active, not recruiting - Clinical trials for Advanced Non Small Cell Lung Cancer

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Start date: August 5, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer

NCT ID: NCT02143271 Completed - Clinical trials for Secondary Hyperparathyroidism

Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Start date: May 2014
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.

NCT ID: NCT02141659 Completed - Clinical trials for Hormone Treatment-naïve Participants With Prostate Cancer

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Start date: May 1, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the tolerability and safety of TAK-385 in hormone treatment-naïve participants with non-metastatic prostate cancer.

NCT ID: NCT02141347 Completed - Clinical trials for Part C: Malignant Mesothelioma

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Start date: May 22, 2014
Phase: Phase 1
Study type: Interventional

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab in combination with MEDI4736 in Japanese Patients with Advanced Solid Malignancies, and when given as a monotherapy of tremelimumab in Second- or Third-line Treatment of Japanese Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

NCT ID: NCT02141074 Completed - Clinical trials for Congenital Bleeding Disorder

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

paradigmâ„¢6
Start date: July 2, 2014
Phase: Phase 3
Study type: Interventional

This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.

NCT ID: NCT02140125 Completed - Healthy Clinical Trials

A Study to Evaluate the Safety of ASP2408 After Subcutaneous Administration to Healthy Male Subjects

Start date: August 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single subcutaneous dose of ASP2408 in non-elderly healthy adult male subjects. The pharmacodynamics of ASP2408 is also being evaluated.

NCT ID: NCT02140047 Completed - Clinical trials for Haemophilus Influenza Type b

Exploratory Clinical Study of MT-2301

Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered with DPT-IPV using ActHIB® as a control in healthy infants.

NCT ID: NCT02139592 Completed - Clinical trials for Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma

Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

Start date: April 17, 2014
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety of brentuximab vedotin (recombinant) for intravenous (IV) infusion (ADCETRIS IV Infusion 50 mg) in patients with relapsed/refractory CD30+ Hodgkin's lymphoma or anaplastic large cell lymphoma in the routine clinical setting, as well as to collect efficacy information for reference.